Lives Worth Living: Addressing The Fentanyl Crisis, Protecting Critical Lifelines, And Combatting...

The Subcommittee on Health of the Committee on Energy and Commerce will hold a hearing on Wednesday, February 1, 2023, at 10 a.m. (EST) in the John D. Dingell Hearing Room, 2123 Rayburn House Office Building. The hearing is entitled “Lives Worth Living: Addressing the Fentanyl Crisis, Protecting Critical Lifelines, and Combatting Discrimination Against Those with Disabilities.”

Legislation
H.R. 171, the "Halt All Lethal Trafficiking of Fentanyl Act" or the "HALT Fentanyl Act"

H.R. 498, the "9-8-8 Lifeline Cybersecurity Responsibillty Act

H.R. 501, the “Block, Report, And Suspend Suspicious Shipments Act”

H.R. 485, the “Protecting Health Care for All Patients Act of 2023”

Witnesses

Panel I:
Kemp Chester
Senior Advisor, International Relations and Supply Reduction
Office of National Drug Control Policy (ONDCP)

Dr. Neerja Gandotra
Chief Medical Officer
Substance Abuse and Mental Health Services Administration (SAMHSA)

Jon C. DeLena
Associate Administrator, Business Operations
Drug Enforcement Administration (DEA)

Panel II:
Kandi Pickard
President and CEO
National Down Syndrome Society (NDSS)

Frederick Isasi, J.D. MPH
Executive Director
Families USA

Molly Cain
Parent Advocate

Dr. Stephen Loyd, MD
Chief Medical Officer
Cedar Recovery

Dr. Timothy Westlake, MD
Emergency Medicine Physician

https://democrats-energycommerce.house.gov/committee-activity/hearings/hearing-on-lives-worth-living-addressing-the-fentanyl-crisis-protecting